Over the last five years, German researcher Georg Schett has made a name for himself as a pioneer in autoimmune disease treatment, showing that CAR-T therapy could be used to reset patients’ immune systems.

He has become a scientific adviser de rigueur for the field, joining a half-dozen startup advisory boards.

Now, for the first time, he’s co-founding a biotech company. But it has no immediate plans to work in CAR-T.